News
IBRX
3.620
+9.04%
0.300
ImmunityBio gets UK MHRA acceptance for marketing application of its bladder cancer treatment
Seeking Alpha · 1d ago
ImmunityBio Is Maintained at Buy by D. Boral Capital
Dow Jones · 1d ago
ImmunityBio Price Target Maintained With a $30.00/Share by D. Boral Capital
Dow Jones · 1d ago
ImmunityBio announces UK acceptance of Anktiva marketing application
TipRanks · 2d ago
IMMUNITYBIO ANNOUNCES UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY ACCEPTED MARKETING AUTHORIZATION APPLICATION FOR ANKTIVA® FOR THE TREATMENT OF PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU
Reuters · 2d ago
ImmunityBio Approves 2024 Executive Bonuses and New Incentives
TipRanks · 2d ago
Weekly Report: what happened at IBRX last week (0203-0207)?
Weekly Report · 5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 02/03 13:01
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 02/03 12:46
Weekly Report: what happened at IBRX last week (0127-0131)?
Weekly Report · 02/03 09:06
Starbucks reports Q1 beat, Frontier proposes Spirit combination: Morning Buzz
TipRanks · 01/29 17:05
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
Dow Jones · 01/29 15:44
Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday
Benzinga · 01/29 15:27
ImmunityBio announces collaboration with Beigene
Seeking Alpha · 01/29 14:26
ImmunityBio enters collaboration with BeiGene on Anktiva trial
TipRanks · 01/29 13:41
ImmunityBio And BeiGene Enter Collaboration For Phase 3 Trial Combining ANKTIVA With Tislelizumab To Improve Survival In NSCLC Patients Resistant To CPI Therapy; ANKTIVA BLA Submission Expected In 2025; Patent Extends To 2035; Study Includes 462 Participants
Benzinga · 01/29 13:32
IMMUNITYBIO INC - PATENT FOR ANKTIVA AND CPI COMBINATIONS EXTENDS TO 2035
Reuters · 01/29 13:30
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
Barchart · 01/29 12:52
After Hours Most Active for Jan 27, 2025 : VTWO, NVDA, AAPL, T, QQQ, IBRX, GOOGL, BAC, AA, GAP, BABA, XOM
NASDAQ · 01/27 21:24
ImmunityBio Is Maintained at Buy by D. Boral Capital
Dow Jones · 01/27 15:08
More
Webull provides a variety of real-time IBRX stock news. You can receive the latest news about Immunitybio Inc through multiple platforms. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.